TMP269

1314890-29-3

N-[[Tetrahydro-4-(4-phenyl-2-thiazolyl)-2H-pyran-4-yl]methyl]-3-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamideTMP269;TMP269N-[[Tetrahydro-4-(4-phenyl-2-thiazolyl)-2H-pyran-4-yl]methyl]-3-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide;BenzaMide, N-[[tetrahydro-4-(4-phenyl-2-thiazolyl)-2H-pyran-4-yl]Methyl]-3-[5-(trifluoroMethyl)-1,2,4-oxadiazol-3-yl]-;TMP269;N-((4-(4-phenylthiazol-2-yl)tetrahydro-2H-pyran-4-yl)Methyl)-3-(5-(trifluoroMethyl)-1,2,4-oxadiazol-3-yl)benzaMide;N-[[Tetrahydro-4-(4-phenyl-2-thiazolyl)-2H-pyran-4-yl]methyl]-3-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide;TMP269, >=98%;N-((4-(4-Phenylthiazol-2-yl)tetrahydro-2H-pyran-4-yl)methyl)-3-(5-(trifluoromethyl)-1,2,4-oxad

TMP269 is a selective class IIa histone deacetylase (HDAC) inhibitor via a non chelating zinc-binding group.

514.52

C25H21F3N4O3S

solid

Amber Vial, -20 ℃ Freezer, under inert atmosphere

13.66±0.46(Predicted)

1.347±0.06(Predicted)